Thompson Siegel & Walmsley LLC Myovant Sciences Ltd. Transaction History
Thompson Siegel & Walmsley LLC
- $6.71 Billion
- Q3 2024
Shares
2 transactions
Others Institutions Holding MYOV
# of Institutions
6Shares Held
61.3KCall Options Held
0Put Options Held
0-
Act Capital Management, LLC Wayne, PA60KShares$01.49% of portfolio
-
Four Thought Financial, LLC Venice, FL1KShares$00.0% of portfolio
-
American Portfolios Advisors Holbrook, NY219Shares$00.0% of portfolio
-
Wipfli Financial Advisors Llc,97Shares$00.0% of portfolio
-
Huntington National Bank Columbus, OH1Shares$00.0% of portfolio
About Myovant Sciences Ltd.
- Ticker MYOV
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 96,802,800
- Description
- Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...